Nanosuspensions: A promising formulation for the new phospholipase A2 inhibitor PX-18

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 322-329

  Pardeike, Jana ^a,b   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Drug nanocrystals; High pressure homogenization; Nanosuspension; Saturation solubility

Indexed keywords

NANOMATERIAL; PHOSPHOLIPASE A2 INHIBITOR; POLYSORBATE 80; PX 18; UNCLASSIFIED DRUG; WETTING AGENT;

ARTICLE; CONTACT ANGLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; REPRODUCIBILITY; STORAGE TEMPERATURE; STRUCTURE ANALYSIS; ZETA POTENTIAL;

ALKANESULFONIC ACIDS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; DRUG STORAGE; NANOSTRUCTURES; OLEIC ACIDS; PARTICLE SIZE; PHOSPHOLIPASES A2; POLYSORBATES; SOLUBILITY; SUSPENSIONS;

EID: 77952884117     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.002     Document Type: Article

References (36)

1. Arni R.K., Ward R.J. Phospholipase A2: a structural review. Toxicon 1996, 34:827-841.
2. Balsinde J., Balboa M.A., Insel P.A., Dennis E.A. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 1999, 39:175-189.
3. Beckman K.B., Ames B.N. The free radical theory of aging matures. Physiol. Rev. 1998, 78:547-581.
4. Bushrab F.N., Müller R.H. Nanocrystals of poorly soluble drugs for oral administration. NewDrugs 2003, 5:20-22.
5. Dennis E.A. History, classification, structure and function of phospholipase A2. Phospholipase A2 Basic and Clinical Aspects in Inflammatory Diseases 1997, Karger, Basel. W. Uhl, T.J. Nevalainen, M.W. Büchler (Eds.).
6. Diaz B.L., Arm J.P. Phospholipase A(2). Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:87-97.
7. Franson R.C., Ottenbrite R.M. Cytoprotective Fatty Moiety Compounds 1997, USA Virginia Commonwealth University, Richmond, VA, USA.
8. Franson R.C., Ottenbrite R.M. Cytoprotective Compounds 2002, USA Virginia Commonwealth University, Richmond, VA, USA.
9. Giron D. Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates. Thermochem. Acta 1995, 248:1-59.
10. Grau M.J., Kayser O., Müller R.H. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int. J. Pharm. 2000, 196:155-159.
11. Grunenberg A. Polymorphism and thermal analysis of pharmaceutical agents. Pharm. Unserer Zeit 1997, 26:224-231.
12. Hecq J., Deleers M., Fanara D., Vranckx H., Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 2005, 299:167-177.
13. Hernandez-Kirstein N. Development and Characterisation of Buparvaquone Nanosuspensions for Pulmonary Delivery in the Treatment of Pneumocystis pneumonia 2006, Institut für Pharmazie, Freie Universität Berlin, Berlin.
14. Jacobs C., Kayser O., Müller R.H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 2000, 196:161-164.
15. Jacobs C., Müller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002, 19:189-194.
16. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
17. Krause K.P., Müller R.H. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int. J. Pharm. 2001, 214:21-24.
18. Latscha H.P., Klein H.A. Analytische Chemie 1995, Springer Verlag, Berlin, Heidelberg.
19. Merisko E. Liversidge nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. Particles 2002, Marcel Dekker, Orlando. J.J. Marty (Ed.).
20. Möschwitzer J. Drug Nanocrystals Preparation by High Pressure Homogenization-The Universal Formulation Approach for Poorly Soluble Drugs 2005, Freie Universität Berlin, Berlin.
21. Möschwitzer, J., Lemke, A., 2005. Method for the gentle production of ultrafine particle suspensions. 017 777.8 DE 10.
22. Müller R.H. Zetapotential und Partikelladung in der Laborpraxis 1996, Wissenschaftliche Verlagsgesellschaft, Stuttgart.
23. Müller R.H., Akkar A. Drug nanocrystals of poorly solible drugs. Encyclopedia Nanosci. Nanotechnol. 2004, 2:627-638.
24. Müller R.H., Böhm B.H.L., Grau M.J. Nanosuspensionen-Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 2. Mitteilung: stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen. Die Pharm. Ind. 1999, 61:74-78. 175-178.
25. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition. I. Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr. 1992, 11:223-236.
26. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition II: characterisation and physical long-term stability of Lipofundin MCT LCT. Clin. Nutr. 1993, 12:298-309.
27. Müller R.H., Jacobs C. Buparvaquone mucoadhesive nanosuspensions: preparation, optimisation and long-term stability. Int. J. Pharm. 2002, 237:151-161.
28. Müller R.H., Peters K. Nanosuspension for the formulation of poorly soluble drugs. 1. Preparation by a size-reduction technique. Int. J. Pharm. 1997, 160:229-237.
29. Müller R.H., Schuhmann R. Teilchengrößenmessung in der Laborpraxis 1996, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
30. Nyström C., Bisrat M. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int. J. Pharm. 1988, 47:223-231.
31. Pardeike, J., Müller, R.H., 2008. Development and validation of a reverse-phase HPLC-UV method for the novel phospholipase A2 inhibitor PX-18. Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS). Atlanta, Georgia, USA.
32. Peters K. Nanosuspensionen-Ein neues Formulierungsprinzip für schwerlösliche Arzneistoffe 1999, Freie Universität Berlin, Berlin.
33. Pruzanski W., Stefanski E., Vadas P., Ramamurthy N.S. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem. Pharmacol. 1997, 53:1901-1907.
34. Schaloske R.H., Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761:1246-1259.
35. Torrado G., Fraile S., Torrado S., Torrado S. Process-indurced crystallite size and dissolution changes elucidated by a variety of analytical methods. Int. J. Pharm. 1998, 166:65-73.
36. Yedgar S., Lichtenberg D., Schnitzer E. Inhibition of phospholipase A(2) as a therapeutic target. Biochim. Biophys. Acta 2000, 1488:182-187.